Indications for liver transplantation in hepatobiliary malignancy
Indications for liver transplantation in hepatobiliary malignancy
复制标题
肝胆恶性肿瘤肝移植的指征
DOI：
10.1002/hep.1840200710
复制
发表时间：
1994
期刊：
影响因子：
13.5
通讯作者：
B. Ringe
中科院分区：
文献类型：
--
作者：
R. Pichlmayr;A. Weimann;B. Ringe
我们总结和讨论了172例患者的个人经验、欧洲肝移植登记的结果和对最近文献的回顾，以确定目前肝移植治疗肝胆恶性肿瘤的适应证。以下情况应被认为是禁忌症：晚期原发性肝肿瘤合并肝外扩散、胆管细胞癌、血管肉瘤和非内分泌原发肿瘤的肝转移。目前，“有利的”适应症包括罕见的肿瘤，如纤维板层癌、上皮样血管内皮瘤、肝母细胞瘤和内分泌肿瘤的转移。进一步的适应症可能是肿瘤II期的不能切除的肝细胞癌和近端胆管癌。肿瘤III期的交界性适应证是肝细胞癌和近端胆管癌。对于仅限于肝脏的晚期肿瘤，移植应该限制在多模式的治疗方案中。尽管对早期可切除的肝细胞癌合并肝硬变的移植有强烈的争论，但这仍然是一个开放的问题，需要在使用相同肿瘤分类的对照研究中进行进一步的研究。考虑到供体器官的有限资源，分离式肝移植允许在不忽视良性疾病的情况下对肿瘤患者进行移植。(《肝病》1994；20：33-40)
Our personal experience with 172 patients, the results from the European Liver Transplant Registry and a review of the recent literature are summarized and discussed to define present indications for liver transplantation in hepatobiliary malignancy. The following conditions should be considered contraindications: advanced primary liver tumors with any extrahepatic spread, cholangiocellular carcinoma, hemangiosarcoma and liver metastases from nonendocrine primary tumor. Currently, “favorable” indications include uncommon tumors such as fibrolamellar carcinoma, epithelioid hemangioendothelioma, hepatoblastoma and metastases from endocrine tumors. Further indications may be nonresectable hepatocellular and proximal bile duct carcinoma in tumor stage II. Borderline indications are hepatocellular and proximal bile duct carcinoma in tumor stage III. In advanced tumors confined to the liver, transplantation should be restricted to multimodality treatment protocols. Although there are strong arguments for transplantation in early resectable hepatocellular carcinoma with underlying cirrhosis, it remains an open issue requiring further investigation in a controlled study using the same tumor classification. With regard to limited resources of donor organs, split‐liver transplantation permits transplantation in tumor patients without neglecting those with benign diseases. (Hepatology 1994;20:33S–40S.)
晚期肝细胞癌肝移植和癌症化疗后生存期延长。
影响因子：
0.9
作者：
Carr,BI;Selby,R;Madariaga,J;Iwatsuki,S;Starzl,TE
通讯作者：
Starzl,TE
肝脏移植治疗肠和胰腺的转移性内分泌肿瘤。
DOI：
--
发表时间：
1989
期刊：
Surgery, gynecology & obstetrics
影响因子：
--
作者：
Makowka,L;Tzakis,AG;Mazzaferro,V;Teperman,L;Demetris,AJ;Iwatsuki,S;Starzl,TE
通讯作者：
Starzl,TE
影响因子：
--
作者：
Yokoyama,I;Todo,S;Iwatsuki,S;Starzl,TE
通讯作者：
Starzl,TE